Argenx SE - Company Profile
Powered by 
All the data and insights you need on Argenx SE in one report.
$295
- Save hours of research time and resources with
our up-to-date Argenx SE Strategy Report
- Understand Argenx SE position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Argenx SE (Argenx) is an immunology company that developed human antibody products for autoimmune diseases. The company's product includes VYVGART, a neonatal Fc receptor blocker, which is used to treat generalized myasthenia gravis in adults. The company’s pipeline products include Efgartigimod, ARGX-117, Cusatuzumab, ARGX-118 and ARGX-119. Argenx in partnership with Leo Pharma, AgoMab, AbbVie and Staten has been licensed to develop products such as ARGX-112, ARGX-114 and ARGX-115. The company develops antibodies using its proprietary technology platforms such as NHance, simple antibody technology, and others. It operates offices in the Netherlands, the United States, Japan, Switzerland and Belgium. Argenxis headquartered in Amsterdam, Noord-Holland, the Netherlands.
Headquarters
Netherlands
Address
Laarderhoogtweg 25, Amsterdam, Noord-Holland, 1101EB
Website
www.argenx.com
Telephone
31 76 3030
No of Employees
1,148
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ARGX (EBR)
Revenue (2022)
$1.2B
198.6%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
58.4%
(2022 vs 2021)
Market Cap*
$22.1B
Net Profit Margin (2022)
XYZ
86.1%
(2022 vs 2021)
* As of and is in US$
Argenx SE premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Products Pipeline: | VYVGART |
| Efgartigimod | |
| ARGX-117 | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In March, the company entered into an agreement with FUJIFILM Diosynth Biotechnologies to provide drug products and finished goods services for efgartigimod in patients with severe autoimmune disease. |
| 2024 | Regulatory Approval | In January, the company received approval for VYVDURA to treat generalized myasthenia gravis in adults. |
| 2023 | Contracts/Agreements | In July, the company entered into an early-stage R&D partnership with Raya Therapeutic Inc for testing combinations of Raya's pipeline of targeted small molecules with a potentially complementary product from Argenx. |
Competitor Comparison
| Key Parameters | Argenx SE | Pharming Group NV | ACE Pharmaceuticals BV | Crossbeta Biosciences BV | Lead Pharma Holding BV |
|---|---|---|---|---|---|
| Headquarters | Netherlands | Netherlands | Netherlands | Netherlands | Netherlands |
| City | Amsterdam | Leiden | Zeewolde | Utrecht | Oss |
| State/Province | Noord-Holland | - | Flevoland | Utrecht | Noord-Brabant |
| No. of Employees | 1,148 | 390 | - | - | 29 |
| Entity Type | Public | Public | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Peter K.M. Verhaeghe | Chairman | Executive Board | 2018 | 64 |
| Tim Van Hauwermeiren | Director; Chief Executive Officer | Executive Board | 2018 | 50 |
| Karl Gubitz | Chief Financial Officer | Senior Management | 2021 | 53 |
| Karen Massey | Chief Operating Officer | Senior Management | 2023 | 44 |
| Luc Truyen | Chief Medical Officer | Senior Management | 2021 | 58 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward